← Eichor
Study identifier: NCT06939257 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Pain Outcomes Associated With Exogenous Hormone Therapy in Adults

Condition: Pain · Gender Minority Individuals  ·  Sponsor: University of Kansas Medical Center

PhaseN/A
Planned participants200
Who can joinAll sexes, 18 Years to 50 Years
Healthy volunteersNo

About this study

TRANSPIRE is an observational study of \~200 individuals who (1) will be initiating gender-affirming hormone therapy (GHT) or (2) are gender minority individuals who do not use GHT. The primary outcome will be to identify how the presence of chronic pain changes overtime with GHT through the use of surveys, quantitative sensory testing (QST), brain MRIs, and qualitative interviews. Following recruitment and consent, participants will complete baseline survey measures and will repeat those measures at 1 months, 3 month, 6 months, and 12 months. QST measures, brain MRIs, and Qualitative Interviews will be offered to participants in cohort (1) and will be completed at baseline and 12 months.

This description comes directly from the study's public registry record.

Talk to the study team

Emily Schulze, MSc  ·  913-588-7630  ·  FACELab@kumc.edu

Miranda McMillan, MSc  ·  913-588-7630  ·  FACELab@kumc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

The University of Kansas Medical CenterKansas City, Kansas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06939257